Screener
Nurix Therapeutics, Inc. NRIX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|
| Proceeds from issuances of common stock in “at the market” financing, net of issuance costs | 18,004 | — |
| Net cash provided by financing activities | 20,041 | 1,479 |
| Net decrease in cash, cash equivalents and restricted cash | (179,275) | (25,737) |
| Cash, cash equivalents and restricted cash at beginning of period | 247,928 | 110,898 |
| Cash, cash equivalents and restricted cash at end of period | $68,653 | $85,161 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities | $314 | $1,082 |
| Right-of-use assets recognized in exchange for lease obligations | $2,765 | $26,708 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s cash & equivalents?
- Nurix Therapeutics, Inc. (NRIX) reported cash & equivalents of $68.65M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Nurix Therapeutics, Inc.'s cash & equivalents decreased by 19.4% year-over-year, from $85.16M to $68.65M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $119.36M to $247.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Nurix Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude